Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Revenue from External Customers by Products and Services

The Company recorded product sales as follows:

	Year Ended December 31,
	2019		2018		2017
	(in thousands)
Bendeka	$	31,182	$	24,568	$	16,225
Belrapzo	29,665		22,853		—
Ryanodex	13,039		20,195		17,500
Other	103		2,769		11,602
Total Product Sales	$	73,989	$	70,385	$	45,327

Schedule of Revenue by Major Customers by Reporting Segments

The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows:

	Year Ended December 31,
	2019		2018		2017
Net revenues
Cephalon, Inc. (Teva) - See Revenue Recognition	77	%	75	%	79	%
Other	23	%	25	%	21	%
	100	%	100	%	100	%

	December 31,
	2019		2018
Accounts receivable
Cephalon, Inc. (Teva) - See Revenue Recognition	80	%	61	%
Other	20	%	39	%
	100	%	100	%

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The anti-dilutive common shares equivalents outstanding at December 31, 2019, 2018, and 2017 were as follows:

	Year Ended December 31,
	2019	2018	2017
Options	2,454,077	1,824,728	1,592,548

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation for basic and diluted net income per share for December 31, 2019, 2018, and 2017:

	Year Ended December 31,
	2019		2018		2017
Numerator
Numerator for basic and diluted earnings per share-net income	$	14,313	31,903		$	51,943
Denominator
Basic weighted average common shares outstanding	13,754,516		14,768,625		15,102,890
Dilutive effect of stock options	384,217		510,026		805,321
Diluted weighted average common shares outstanding	14,138,733		15,278,651		15,908,211
Basic net income per share
Basic net income per share	$	1.04	$	2.16	$	3.44
Diluted net income per share
Diluted net income per share	$	1.01	$	2.09	$	3.27